4-(Bromomethyl)phenylboronic acid | CAS:68162-47-0

We serve 4-(Bromomethyl)phenylboronic acid CAS:68162-47-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-(Bromomethyl)phenylboronic acid

Product Name: 4-(Bromomethyl)phenylboronic acid
Other Name:
4-(Bromomethyl)phenylboronic acid
[4-(bromomethyl)phenyl]boronic acid
CAS No: 68162-47-0
MF: C7H8BBrO2
MW: 214.85200
Density: 1.57 g/cm3
Boiling point: 343.1ºC at 760 mmHg
Melting point: 78-81°C
Flash point: 161.3ºC
Refractive index: 1.582
UN Number: Non-dangerous goods
Transport hazard class: Non-dangerous goods
Packing group: Non-dangerous goods
 
Specification
Appearance: White powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like 4-(Bromomethyl)phenylboronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[4-(bromomethyl)phenyl]boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[4-(bromomethyl)phenyl]boronic acid Use and application,4-(Bromomethyl)phenylboronic acid technical grade,usp/ep/jp grade.


Related News: It is delivered to hospitals and pharmacies until it reaches the patient.Methyl 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoate manufacturer The measure starts on February 4, according to South Korean Prime Minister Chung Sye-kyun.N-(chloromethyl)-N-phenylcarbamoyl chloride supplier Take penicillin industrial salt and vitamin C as examples. They are the two strategic varieties of chemical raw materials in China, and they are also representatives of severe overcapacity.4-(Trifluoromethyl)benzaldehyde vendor The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.”Out of an abundance of caution and based on the latest advice from leading health experts, we’re closing all our corporate offices, stores and contact centers in mainland China through February 9.”